

Manufacturer's Declaration

in relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to

- the validity of certificates issued under Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) or Council Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) and/or¹
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

Manufacturer name	Direct Healthcare Group Ltd.			
Manufacturer address and contact details	Withey Court, Western Industrial Estate, Caerphilly, CF83 1BF, United Kingdom			
Single Registration Number (SRN) (if available)	UK-MF-000037574			

Authorised Representative name (if applicable)	Direct Healthcare Group Sverige AB			
Authorised Representative address and contact details	Torshamnsgatan 35, SE-164 40 Kista, Sweden			
Single Registration Number (SRN) (if available)	SE-AR-000014155			

Notified body name (if applicable)	PCBC	□ See attached schedule
Notified body number (if applicable)	1434	□ See attached schedule

¹ The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.

Page 1 of 5

Direct Healthcare Group Ltd Unit 6/10 Withey Court, Western Industrial Estate, Caerphilly, CF83 1BF, UK Sales Office +44 (0) 800 043 0881 F +44 (0) 845 459 9832 E info@directhealthcaregroup.com www.directhealthcaregroup.com

Directive Certificate number(s) to which this confirmation is made (if applicable)	1434-MDD-302/2020	□ See attached schedule
Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable)	16/06/2023	See attached schedule
End date of extended validity/transition period	31/12/2028	See attached schedule

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** (or see attached schedule, if multiple certificates) the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*²
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

> Directive Certificate(s) as listed above or in the attached schedule

• Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

Choose applicable statements:

- Expired *before* 20 March 2023:
 - □ Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII to this Regulation for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of a device(s) intended to substitute that/those device(s), or
 - □ A Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 59(1) MDR (may be provided upon request), or
 - □ A Competent Authority has required the manufacturer, in accordance with Article 97(1) MDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

Choose one of the following statements only if a derogation per Article 59(1) or a requirement per Article 97(1) has been granted by a Competent Authority:

 $^{^2}$ The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body

- □ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- □ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.
- Expired/expires *after* 20 March 2023:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- □ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

> Upclassified devices

In case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body:

Choose one applicable statement:

- □ Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitutes and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- □ We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

> Quality Management System (QMS)

Choose one applicable statement:

- □ A QMS in accordance with Article 10(9) MDR will be put in place by no later than 26 May 2024.
- A QMS in accordance with Article 10(9) MDR is in place.
- □ A notified body has issued the attached certificate for the MDR-compliant QMS.

> Device(s) as listed in the attached schedule

- The device(s) continue to comply with the AIMDD or MDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Page **3** of **5**

Direct Healthcare Group Ltd Unit 6/10 Withey Court, Western Industrial Estate, Caerphilly, CF83 1BF, UK

Sales Office +44 (0) 800 043 0881 F +44 (0) 845 459 9832 E info@directhealthcaregroup.com www.directhealthcaregroup.com

Signed for and on behalf of the manufacturer:

 Full Company Name: Direct Healthcare Group Limited

 Location & Date: Caerphilly, United Kingdom
 06 NOV 2024

 Signature, Print Name, Title:
 RW.Macdonald

Robert Macdonald, Group Regulatory Affairs Director

Contact Details (at least email): rmacdonald@talleygroup.com

Schedule of Devices

The above Manufacturer's Declaration is valid for the following devices:

Identification of the device(s) ³ (e.g., device name, family/group name device model or catalogue number)	Risk Class Under MDD	Directive Certificate number(s) to which this confirmation is made (if applicable)	Original expiry date as indicated on the Directive Certificate (s) prior to the extension of the validity (if applicable)	Notified Body name and number that issued the Directive Certificate (if applicable)	Notified Body name and number where the MDR application was lodged/contract signed (if applicable)	End date of extended validity / transition period	Substitute Device(s) (if applicable)	Proposed timeline for submission of Technical Documentation (MM/YYYY)
Dyna-Form Range (PAC System; Pump and Mattress/ Cushion) Dyna-Form Mercury Advance Range Dyna-Form Mercury Advance Bari Range Dyna-Form Mercury Advance SMARTcare Range Dyna-Form Mercury Advance Community Range Dyna-Form Mercury Advance Trolley Range Dyna-Form SMARTresponse Range	lla	1434-MDD- 302/2020	16/06/23	PCBC 1434	DQS 0297	31/12/2028	N/A	10/2025
Dyna-Form Air Range (PAC System; Pump and Mattress) Dyna-Form Air Suresse Range Dyna-Form Air Pro-Plus Range	lla	1434-MDD- 302/2020	16/0623	РСВС 1434	DQS 0297	31/12/2028	N/A	10/2025

³ for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)